Therapies for multiple myeloma have evolved very rapidly over the past several years with a significant improvement in outcomes. However, access and availability of drugs remain variable and dictated by regional approval and reimbursement strategies. Consequently, practice patterns are variable and patient access is unequal. Given the rapidly accumulating data and available options, treatment decisions are not straightforward. To combat this disparity, the International Myeloma Society has started the Therapeutic Map (TMAP) initiative.
TMAP is a web program that provides region- and country-specific guidance to help hematologists and oncologists in the care of multiple myeloma patients, by providing the user with availability and coverage information in each region or country.
Country representatives, global coordinators, and super admins can all sign in here. Your view is scoped to your role.
New country representative? Register your country
One verified representative per country contributes and maintains that country's data. Global Coordinators and Super Admins are provisioned separately.